# Length of Effect of Extended Release Aspirin on Platelets in Patients With Diabetes and Heart Disease

> **NCT02370680** · PHASE1 · COMPLETED · sponsor: **New Haven Pharmaceuticals, Inc.** · enrollment: 41 (actual)

## Conditions studied

- Cardiovascular Disease

## Interventions

- **DRUG:** Aspirin
- **DRUG:** Durlaza™

## Key facts

- **NCT ID:** NCT02370680
- **Lead sponsor:** New Haven Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02
- **Primary completion:** 2015-07
- **Final completion:** 2015-07
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2015-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02370680

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02370680, "Length of Effect of Extended Release Aspirin on Platelets in Patients With Diabetes and Heart Disease". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT02370680. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*